Blackrock Neurotech is thrilled to announce a groundbreaking funding success, having raised $200 million to further its mission of restoring independence and function to individuals with neurological disorders. As the world leader in brain-computer interface (BCI) technology, Blackrock Neurotech unites a team of top engineers, neuroscientists, and visionaries who are dedicated to developing advanced neural implants aimed at transforming the lives of those affected by conditions such as ALS, Alzheimer’s, Parkinson’s, epilepsy, and paralysis disorders. This significant investment will enable us to accelerate the development of our next-generation BCI systems, enhancing our pioneering technology that has already empowered patients to reclaim movement and communication for over 30,000 days.
Since its inception in 2004, our flagship product, the MoveAgain BCI, has demonstrated exceptional potential and was awarded Breakthrough Designation by the FDA in 2021. With this funding, we are poised to expand our clinical trials and advance our efforts towards commercial availability, expected later this year. We believe that with greater resources, we can continue to push the boundaries of innovation, working hand-in-hand with over 500 global institutional partners to not only enhance our current systems but also explore new applications that can address the most complex neurological challenges. Join us in changing lives today—together, we can make a lasting impact on the world of neuroscience and beyond. Connect with us through our website and social media channels to learn more about our journey and opportunities to get involved.
